Optical coherence tomography in multiple sclerosis

Elliot Frohman, Fiona Costello, Robert Zivadinov, Olaf Stuve, Amy Conger, Heather Winslow, Anand Trip, Teresa Frohman, Laura Balcer

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

Original languageEnglish (US)
Pages (from-to)853-863
Number of pages11
JournalLancet Neurology
Volume5
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Optical Coherence Tomography
Multiple Sclerosis
Biomarkers
Optical Imaging
Demyelinating Diseases
Axons
Retina
Wounds and Injuries

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Frohman, E., Costello, F., Zivadinov, R., Stuve, O., Conger, A., Winslow, H., ... Balcer, L. (2006). Optical coherence tomography in multiple sclerosis. Lancet Neurology, 5(10), 853-863. https://doi.org/10.1016/S1474-4422(06)70573-7

Optical coherence tomography in multiple sclerosis. / Frohman, Elliot; Costello, Fiona; Zivadinov, Robert; Stuve, Olaf; Conger, Amy; Winslow, Heather; Trip, Anand; Frohman, Teresa; Balcer, Laura.

In: Lancet Neurology, Vol. 5, No. 10, 10.2006, p. 853-863.

Research output: Contribution to journalArticle

Frohman, E, Costello, F, Zivadinov, R, Stuve, O, Conger, A, Winslow, H, Trip, A, Frohman, T & Balcer, L 2006, 'Optical coherence tomography in multiple sclerosis', Lancet Neurology, vol. 5, no. 10, pp. 853-863. https://doi.org/10.1016/S1474-4422(06)70573-7
Frohman, Elliot ; Costello, Fiona ; Zivadinov, Robert ; Stuve, Olaf ; Conger, Amy ; Winslow, Heather ; Trip, Anand ; Frohman, Teresa ; Balcer, Laura. / Optical coherence tomography in multiple sclerosis. In: Lancet Neurology. 2006 ; Vol. 5, No. 10. pp. 853-863.
@article{67b289dee471400e8e431fa2190f9d4a,
title = "Optical coherence tomography in multiple sclerosis",
abstract = "We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.",
author = "Elliot Frohman and Fiona Costello and Robert Zivadinov and Olaf Stuve and Amy Conger and Heather Winslow and Anand Trip and Teresa Frohman and Laura Balcer",
year = "2006",
month = "10",
doi = "10.1016/S1474-4422(06)70573-7",
language = "English (US)",
volume = "5",
pages = "853--863",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Optical coherence tomography in multiple sclerosis

AU - Frohman, Elliot

AU - Costello, Fiona

AU - Zivadinov, Robert

AU - Stuve, Olaf

AU - Conger, Amy

AU - Winslow, Heather

AU - Trip, Anand

AU - Frohman, Teresa

AU - Balcer, Laura

PY - 2006/10

Y1 - 2006/10

N2 - We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

AB - We do not have currently satisfactory clinical and anatomical correlates to gauge disability in multiple sclerosis. Structural biomarkers (such as MRI) are hindered because they cannot precisely segregate demyelination from axonal elements of tissue injury within the CNS. Axonal degeneration in multiple sclerosis is related to irreversible disability, which suggests that the confirmation of neuroprotective strategies needs highly quantifiable measures of axon loss that can be correlated with reliable measures of physiological function. The coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography, enables us to begin to understand how structural changes in the visual system influence function in patients with multiple sclerosis. In this review, we consider the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=33750592482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750592482&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(06)70573-7

DO - 10.1016/S1474-4422(06)70573-7

M3 - Article

C2 - 16987732

AN - SCOPUS:33750592482

VL - 5

SP - 853

EP - 863

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 10

ER -